Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Completed · Phase 2

Conditions studied: Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or without thalidomide in treating patients who have metastatic prostate cancer.

Key facts

Study ID

NCT00020046

Run by

National Institutes of Health Clinical Center (CC)

Starts

1999-12-01

Expected to finish

2003-09-01

Last updated by the study team

2023-10-31

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Medicine Branch — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.